DAY ONE - TUESDAY FEBRUARY 23rd, 2021

8:30 am
IO360°/Cell & Gene Therapy Virtual Platform Opens

This is an opportunity to explore the platform, reach out to fellow attendees and visit the technology and service companies working specifically in immuno-oncology R&D. Partnering Meetings will also be taking place during this time on Meeting Mojo.

9:00 am
Opening Remarks & Welcome
Kate Woda
Director, IO360°

9:10 am
Analyst Evaluation: Cancer Cell Therapy Landscape, Trends and Future Outlook
Asthika Goonewardene, MBA
Managing Director, Senior Biotech Analyst, Truist Securities

9:30 am
FDA's Efforts to Facilitate the Development of Cell and Gene Therapies for Cancer
Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research (CBER), FDA

9:50 am
Deep Dive: Addressing Key Issues Of Cell/ Gene Therapy

This discussion, led by internationally recognized T cell therapy expert Dr Michael Kalos, will provide a deep dive into key cell therapy challenges including:
• How to overcome the scientific challenges with allogenic cell therapy?
• How do we make an impact on solid tumors?
• Where do we go beyond t-cells?
• As the field continues to advance how do we think about cell therapy combinations?

Moderated by:
Michael Kalos, PhD
Former EVP & Head, R&D / Independent Consultant, ArsenalBio / Next Pillar Consulting

Panelists:
May Daher, MD
Assistant Professor, Stem Cell Transplant and Cellular Therapy Department, MD Anderson Cancer Center
Hy Levitsky, MD
President, Research and Development, Century Therapeutics
Pascal Touchon
President & CEO, Atara Biotherapeutics
Nicholas Haining, BM, BCh
VP, Discovery Oncology, Merck

10:30 am
Speaker Meet/Greet Breakouts & Visit the Technology & More Section

This 10 minute session is allotted to meet the speakers from the previous talks and an opportunity to visit the Technology & More section of the virtual platform.

10:40 am
Ten Minute Break

10:50 am
Visionary Entrepreneur Fireside Chat

Allogene's Executive Chairman and Co-founder, Dr Arie Belldegrun joins life science CEO leader Fred Hassan in a fireside keynote chat on science, culture, vision and the future of treating cancer for patients.

Arie Belldegrun, MD
Executive Chairman & Co-founder, Allogene Therapeutics
with
Fred Hassan, MBA
Director, Healthcare and Consumer, Warburg Pincus

11:10 am
Biotech CEO Leadership on the Business and Science of Cell and Gene Therapy

Biotech leaders join us to provide their perspectives and insights on the current cell and gene therapy space, the impact of COVID-19 and additional opportunities to advance cell and gene therapy R&D.

Moderated by:
Fred Hassan, MBA
Director, Healthcare and Consumer, Warburg Pincus

Panelists:
David Chang, MD, PhD, President, CEO & Co-founder, Allogene Therapeutics
Ken Drazan, MD Co-founder & CEO, ArsenalBio
Maria Fardis, PhD President and CEO, IOVANCE Biotherapeutics
Vijay Reddy, MD Chief, Research and Development Officer, Tmunity
Dolores Schendel, PhD CEO & CSO, Medigene AG
Pascal Touchon President & CEO, Atara Biotherapeutics
Maria Fardis

12:10 pm
Quick Fire Presentations on Solutions that Support Immuno-Oncology R&D

12:20 pm
Lunch
### BioPharma Cell/Gene Therapy Strategies

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:10 pm</td>
<td>Five Minute Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15 pm EST</td>
<td>Update on Adaptimmune’s Cell Therapy Programs</td>
<td>Helen Tayton-Martin, PhD&lt;br&gt;Chief Business Officer, Adaptimmune</td>
<td>Adaptimmune</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Engineering Gamma Delta T cells with CARs and T Cell Receptors</td>
<td>Stewart Abbot, PhD&lt;br&gt;Chief Scientific and Operating Officer, Adicet Bio</td>
<td>Adicet Bio</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Enhanced NK Cell Function to Provide Resistance to TGFβ</td>
<td>James Trager, PhD&lt;br&gt;Chief Scientific Officer, Nkarta Therapeutics</td>
<td>Nkarta Therapeutics</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Building the Takeda Cell Therapy Portfolio Through Collaborations</td>
<td>Gary Shapiro, PhD&lt;br&gt;Director, Immunology Research, Takeda Pharmaceuticals</td>
<td>Takeda Pharmaceuticals</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors</td>
<td>Maria Fardis, PhD&lt;br&gt;President and CEO, IOVANCE Biotherapeutics</td>
<td>IOVANCE Biotherapeutics</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Neoantigen directed PBL-based Cell Therapy can Achieve High Breadth and Purity Against Tumor Specific Targets</td>
<td>Tom Davis, MD&lt;br&gt;Chief Medical Officer, Genocea</td>
<td>Genocea</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Next-generation Sequencing clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Blood Cancers</td>
<td>Thomas Manley, MD&lt;br&gt;VP, Clinical Development and Medical Affairs, Adaptive Biotechnologies</td>
<td>Adaptive Biotechnologies</td>
</tr>
</tbody>
</table>

**KEYNOTE**

**12:45 pm**

**How Synthetic Biology & Synthetic Circuits Can be Implemented into Cell Therapy to Advance the Field**

In this talk, Dr Kole Roybal will discuss how his lab is engineering immune cells (e.g. the T cell) to better sense diseases such as cancer with high fidelity. He will also discuss how to utilize synthetic biology to customize and control immune cells such that they perform specific therapeutic functions within the tumor to enhance efficacy and mitigate the risk of toxicity of these living drugs. Overall, the objective is to seek to engineer control over the sense and response capabilities of therapeutic cells such that they reliably sense and treat complex diseases with more specificity and potency than small molecules or biologics.

**Kole Roybal, PhD**  
Assistant Professor, Microbiology & Immunology, University of California, San Francisco

---

**BioPharma Cell/Gene Therapy Strategies**
2:15 pm  
**Speaker Meet/Greet Breakouts & Visit the Technology & More Section**  
This 10 minute session is allotted to meet the speakers from the previous talks and an opportunity to visit the Technology & More section of the virtual platform.

2:25 pm  
**Regulatory Opportunities to Accelerate the Development of Cell Therapies**  
This panel will discuss and describe how current regulatory and policy discussions (FDA guidance, PDUFA) could be setup to facilitate the science and innovation of cell therapies. Key topics include:
• Opportunities to accelerate entry into the clinic for exploratory studies  
• Explore lighter cGMP requirements for early investigational products/phases  
• Identify how to best pivot from that data (if positive) to a full fledged phase I/II IND (Role of parent and cousin INDs)  

*Moderated by:*  
**Mark Stewart, PhD**  
Vice President, Science Policy, Friends of Cancer Research  

*Panelists:*  
**Lisa Butterfield, PhD**  
VP, Research and Development, Parker Institute for Cancer Immunotherapy  
**Julie K Jadlowsky, PhD**  
Director, Translational Science, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania  
**Chris Ramsborg, PhD**  
Vice President, Cell and Gene Therapy Process Science & Technology, BMS  
**Aiman Shalabi, PharmD**  
VP R&D, Cell and Gene Therapies, GSK

3:05 pm  
**Operational Execution of Cell/Gene Therapy Programs: Challenges and Opportunities**  
This discussion will address the operational challenges in the cell and gene therapy space pertaining to supply chain operations and site activation. Key areas include:  
• Identifying differences between traditional execution of getting these programs delivered? How is it different?  
• What are the new technologies out there helping us to try and solve this problem? What digital platforms are being pushed?  
• What are the issues at the site level that we need to be aware of?  
  o Each group is trying to implement their own standards, and those standards differ across companies.  
  o The sites are trying to cater to multiple types of standards.  
  There is no harmonization at the site level.

*Moderator:*  
**Rachel Gaskell**  
Senior Director, Clinical Development, GSK  

*Panelists:*  
**Shree Patel, PhD**  
SVP, Clinical Operations, Achilles Therapeutics  
**Deborah Phippard, PhD**  
Global Head, Research, Precision for Medicine  
**Scott Welden**  
Senior Project Manager, Novel and Emerging Therapies, Oncology and Hematology Business Unit, Syneos Health

3:45 pm  
**Cell/Gene Therapy Debate**  

*3:45 pm  
**Autologous vs Allogeneic**  
**Rafael Amado, MD**  
EVP, Research and Development & CMO, Allogene Therapeutics  
**Kristen Hege, MD**  
SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy, BMS  

*Moderated by:*  
**Aiman Shalabi, PharmD**  
VP R&D, Cell and Gene Therapies, GSK

4:15 pm  
**End of Day One**
10:55 am
Targeting the ICOS Pathway with Feladilimab, a Differentiated Agonist Antibody for Cancer Immunotherapy
Sapna Yadavilli
Clinical Biomarker Director, Experimental Medicine Unit, Oncology, GSK

11:10 am
Speaker Meet/Greet Breakouts & Visit the Technology & More Section
This 10 minute session is allotted to meet the speakers from the previous talks in the preclinical session and an opportunity to visit the Technology & More section of the virtual platform.

11:20 am
Ten Minute Break

11:30 am
Next Generation Immune Checkpoints: Deciphering Key Roles in the TME
Catherine Sabatos-Peyton, PhD
Executive Director, Head of Immune Modulation, Novartis Institutes for BioMedical Research

11:45 am
Preclinical and Translational updates on SEA-TGT, an anti-TIGIT Antibody for Multiple Tumor Types
This talk will include robust preclinical mechanisms of action for Seagen’s sugar engineers antibody, SEA-TGT, an anti-TIGIT antibody, along with early clinical findings, phase 1 design and preliminary biomarker data.
Haley Neff-LaFord, PhD, DABT
Director, Toxicology and Translational Sciences Team Lead, Seagen

12:00 pm
FT536 – An iPSC-derived, Multiplexed Engineered CAR MICA/B NK Cell Product Targeting Solid Tumors
• Induced pluripotent stem cells (iPSCs) serve as a unique starting cell source for off-the-shelf cancer immunotherapy
• Through single cell engineering, the derived iPSC MCB is renewably manufactured to generate homogenous, cost effective and available on-demand engineered CAR-T and CAR-NK cells
• CAR-MICA/B is a novel pan-tumor targeting strategy
• FT536 is an off-the-shelf NK cell uniformly consisting of four anti-tumor modalities that uniquely synergize with other therapeutic approaches such as mAbs and radiation therapy for an effective elimination of various solid tumors
Bahrem (Bob) Valamehr, PhD
Chief Development Officer, Fate Therapeutics
### Choice between Advancements in IO Imaging and Clinical Operations

#### Advancements in IO Imaging

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
</table>
| 1:00  | Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST | Gregory Goldmacher, MD, PhD  
Executive Director, Translational Biomarkers & Head, Clinical Imaging,  
Merck Research Laboratories                                                        |
| 1:15  | Applying a Novel AI Approach to Concluded Clinical Trial Data to Predict Response to Cancer Immunotherapy | Anant Madabhushi, PhD  
Donnell Institute Professor, Director, Ctr for Computational Imaging &  
Personalized Diagnostics, Departments of Biomedical Engineering, Urology,  
Radiology, Pathology, Radiation Oncology, Electrical Eng & Comp Science  
and Gen Med Sciences, Case Western Reserve University |
| 1:30  | Imaging Endpoints Case Study                                             | Ron Korn, MD, PhD  
Founder & CMO, Imaging Endpoints                                                 |

#### Clinical Operations

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
</table>
| 1:00  | Biomarker Focused IO Clinical Trial Design                               | Chris Cabanski, PhD  
Director, Biostatistics, Parker Institute for Cancer Immunotherapy               |
| 1:15  | Applying Predictive Machine-Learning to Improve Enrollment in Biomarker-Driven Clinical Trials | Janssen R&D TBD                                                                 |
| 1:30  | Addressing Operational Challenges Impeding Patient Access to Trials: Next Steps | Jacob Aptekar, MD, PhD  
Senior Director, Product Management (Integrated Evidence), Acorn AI, a Medidata company |
## Choice between Advancements in IO Imaging and Clinical Operations

### Advancements in IO Imaging

**1:45 pm** Radiomics and AI for Predicting Tumor Response in Immuno-Oncology  
Charles Ferte, MD, PhD  
Senior Director, Global Project Leader (Product Development Team Leader), Oncology R&D, AstraZeneca

**2:00 pm** Reserved Case Study

**2:15 pm** Interventional Imaging in Immunotherapy: Current Approaches, Future Directions  
- Future of immune imaging in the relation to immune response and where we are going with it  
- How we can use imaging to elicit new paradigms for clinical trials  
- Utilizing imaging to understand the kinetics of response; early progression through imaging and late response, etc.  
- Data on imaging for response using radiolabeled pd1 antibodies, immuno PET  
- Imaging in the CNS to evaluate response  
- PET Imaging to detect the release of granzymes by activated immune cells  
- PET Tracers with CD8 cells and how that relates to response

Moderated by:  
Omid Hamid, MD  
Chief, Research and Immunotherapy / Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute / Cedars-Sinai CANCER

Panelists:  
Gregory Goldmacher, MD, PhD  
Executive Director, Translational Biomarkers & Head, Clinical Imaging, Merck Research Laboratories  
Ron Korn, MD, PhD  
Founder & CMO, Imaging Endpoints  
Alexander Menzies, PhD  
Medical Oncologist and Associate Professor of Melanoma Medical Oncology, Imaging Endpoints

### Clinical Operations

**1:45 pm** Operational Continuity: Dealing with Disruptions of a Pandemic  
This panel focuses on operational pandemic management for clinical trials and how to deal with the trial disruptions in a situation such as we have been experiencing.

Moderated by:  
Andy Lee  
SVP, Global Head, Clinical Operations, Merck

Panelists:  
Carol Haddad  
Executive Director, Oncology Clinical Sciences and Study Management, Merck  
Michele Sample, MD  
Vice President, Late Stage Oncology Clinical Operations, AstraZeneca  
Simon Trowell  
VP, Clinical Development Quality & Risk Management, GSK  
Jim Wise  
Executive Director & Head of Center for Immuno-oncology, Cellular, and Gene Therapy, PRA Health Sciences

**2:45 pm** Break

**3:15 pm** New Biomarkers and Ongoing Challenges for Immuno-Oncology: Who, When, What  
- Recent data on current and emerging IO biomarkers that guide treatment selection across tumor types  
- Challenges and limitations associated with current and emerging biomarkers in patient selection for IO trials and therapies  
- Strategic and operational considerations to incorporate biomarker testing including biopsy sampling, testing platforms, and interpretation

Angela Qu, MD, PhD  
Vice President, Translational Medicine, Parexel
3:30 pm  
**TCR-engineered T cells Targeting HPV-16 E7 for Patients with Metastatic HPV-Associated Epithelial Cancers**

- We conducted a first-in-human, phase I clinical trial testing TCR-engineered T cells targeting HPV-16 E7 in patients with metastatic HPV-associated epithelial cancers. Objective clinical responses were seen in 6 of 12 patients including 4 of 8 patients with anti-PD-1 refractory disease.
- Translational research studies indicate that clinical activity may be limited by tumor-intrinsic genetic defects in molecules important for antigen presentation and interferon response.
- Strategies being explored to improve clinical outcomes include the use of membrane-tethered cytokines and treatment at earlier stages of disease.

**Scott Norberg, DO**  
*Assistant Research Physician, Genitourinary Malignancies Branch, National Cancer Institute (NCI)*

3:45 pm  
**Adaptive Biotechnologies Case Study**  
Sharon Benzeno, PhD  
*Chief Business Development Officer, Adaptive Biotechnologies*

**4:00 pm**  
**Visions of the Future for Cancer Immunotherapy: Year 2040**  
Cancer immunotherapy experts Dr Dan Chen, IGM Biosciences and Dr David Chang, Allogene, present in a Sci-Fi-style fashion, how they envision cancer immunotherapy working in 10-20 years. They will have the opportunity to critique each others approach and will open the dialogue to the audience.

Attendees will gain a better understanding of:
- The challenges that immunotherapy has today
- How technology and science can improve therapeutics over the next 10 – 20 years
- How different immunotherapies might interact

**David Chang, MD, PhD**  
*President, CEO & Co-founder, Allogene Therapeutics*

**Daniel Chen, MD, PhD**  
*Chief Medical Officer, IGM Biosciences*

**Moderated by:**  
**Charles Graeber**  
*Award-winning Journalist and Author of The Breakthrough: Immunotherapy and the Race to Cure Cancer*

**4:30 pm**  
10 min Break

**4:40 pm**  
**Zoom Small Group Interactive Discussions**  
The concluding afternoon of day one will be dedicated to 30 minute small group discussion choices. These interactive discussions are first come first serve and have limited capacity. Registration is required in advance. Registered IO360° attendees may choose one discussion group to attend live over the course of the conference.

To register for the discussion topic of your choice please email service@tcflc.org with the Subject Line: IO360° Group Discussion Choice.

Topics to date include:

**Biotech Roundtable on Developing Combination Strategies**
This roundtable, designed for small and emerging biotechs, will answer questions from experts on how to develop combination strategies.

- How do you design combination clinical trials
- How do you to this when your combining partner has mono therapy activity
- What would it take for small biotechs to get set up for combination strategies

**Led by:**  
**Priti Hegde, MD**  
*Chief Scientific Officer, Foundation Medicine*

**Additional Topics TBD**
Evaluating PD1 Benefit After PD1 Failure

In this talk, Dr. Naiyer Rizvi, Columbia University, sheds light on the benefit of giving PD1 to PD1 patients specifically addressing:

- What do we know about any setting, lung cancer and otherwise, where PD1 has been given after PD1 and a conclusion can be drawn, what effect that has? What does PD1 alone do after PD1 failure?
- What do we know about response rate, PFS and survival in terms of clinical outcomes after PD1?
- What do we know about combinations of PD1 after PD1?

Naiyer Rizvi, MD
Price Family Professor of Medicine; Director, Thoracic Oncology; Co-Director, Cancer Immunotherapy, Columbia University Irving Medical Center
Choice Between 2 Breakout Sessions

### Neoadjuvant & Adjuvant Data

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am</td>
<td>Updates on Bladder Cancer in the Neoadjuvant Setting</td>
<td>Andrea Necchi, MD, Associate Professor / Director of Genitourinary Medical Oncology, Vita-Salute San Raffaele University / IRCCS San Raffaele Hospital</td>
</tr>
<tr>
<td>10:45 am</td>
<td>Updates on Bladder Cancer in the Adjuvant Setting</td>
<td>Andrea Apolo, MD, Head, Bladder Cancer Section, National Cancer Institute</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Updates on Lung Cancer in the Adjuvant and Neoadjuvant Setting</td>
<td>Joshua E Reuss, MD, Assistant Professor of Medicine, Georgetown Lombardi Comprehensive Cancer Center</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Triple Negative Breast Cancer in the Neoadjuvant Setting</td>
<td>Elizabeth A Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, Director of the Breast Immuno-Oncology Program, Brigham and Women's Hospital, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>11:30 am</td>
<td>Neoadjuvant/Adjuvant Expert Discussion</td>
<td>Andrea Apolo, MD, Head, Bladder Cancer Section, National Cancer Institute Andrea Necchi, MD, Associate Professor / Director of Genitourinary Medical Oncology, Vita-Salute San Raffaele University / IRCCS San Raffaele Hospital Elizabeth A Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, Director of the Breast Immuno-Oncology Program, Brigham and Women's Hospital, Dana-Farber Cancer Institute Joshua E Reuss, MD, Assistant Professor of Medicine, Georgetown Lombardi Comprehensive Cancer Center</td>
</tr>
</tbody>
</table>

### Cancer Vaccines

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am</td>
<td>Development of Neoantigen Specific Vaccines</td>
<td>Karin Jooss, PhD, Chief Scientific Officer, Gritstone Oncology</td>
</tr>
<tr>
<td>10:45 am</td>
<td>Next Generation Synthetic Vaccines</td>
<td>Anish Suri, PhD, President &amp; Chief Scientific Officer, Cue Biopharma</td>
</tr>
<tr>
<td>11:00 am</td>
<td>A Multifaceted Approach to ImmunoTherapy Including a Therapeutic Vaccine</td>
<td>Jeffrey Schlom, PhD, Chief, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Cancer Vaccines and T Cell Therapy</td>
<td>Mary L (Nora) Disis, MD, Helen B Slonaker Endowed Professorship for Cancer Research; Professor, Department of Medicine, Division of Oncology; Director, Tumor Vaccine Medical Oncology, University of Washington Medicine</td>
</tr>
<tr>
<td>11:30 am</td>
<td>Vaccine Expert Discussion</td>
<td>Karin Jooss, PhD, Chief Scientific Officer, Gritstone Oncology Jeffrey Schlom, PhD, Chief, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute Anish Suri, PhD, President &amp; Chief Scientific Officer, Cue Biopharma Mary L (Nora) Disis, MD, Helen B Slonaker Endowed Professorship for Cancer Research; Professor, Department of Medicine, Division of Oncology; Director, Tumor Vaccine Medical Oncology, University of Washington Medicine</td>
</tr>
</tbody>
</table>
11:50 am
Quick Fire Presentations on Solutions that Support Immuno-Oncology R&D

12:00 pm
Lunch

**AFTERNOON KEYNOTE**

12:30 pm
Cancer Vaccination: Lessons Learned
Dr Lisa Butterfield, Parker Institute for Cancer Immunotherapy will present recent studies on key aspects of cancer vaccine biology that impact in vivo immunity and clinical outcome in patients, as well as future directions for where cancer vaccines may fit into the immunotherapy armamentarium.

Lisa Butterfield, PhD
VP, Research and Development, Parker Institute for Cancer Immunotherapy

1:15 pm
Panel: Role of China in the BD Process
This panel will bring together chinese biotechs to share how they are partnering with additional IO companies to advance cancer treatments for patients. This will include partnering strategies and decision making.

Moderated by:
Andrew Baum, MD
Managing Director, Equity Research, Citi

Panelists:
Meeta Chatterjee, PhD
SVP, Global Business Development, Legend Biotech
Angus Grant, PhD
SVP, Chief Business Executive, BeiGene
Weimin Tang
EVP, Global Business Head, I-Mab Biopharma

1:45 pm
New Dynamics of BD and Covid and the Impact on IO - Lessons Learned
GSK Speaker TBD

**ANALYST KEYNOTE**

12:55 pm
Analyst Keynote: What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum
In this talk, Dr Andrew Baum will provide an evaluation of the IO landscape and advancements from 2020 and include his annual top 10 target recommendations.

Andrew Baum, MD
Managing Director, Equity Research, Citi

2:05 pm
Dealmaking & Collaborations in the Time of COVID19
This panel will address the current nature of deals and collaborations during a pandemic where business developments have been conducted in a remote manner. Key topics:
- How have deals and collaborations approach changed as a result of COVID19 and how has the industry adapted?
- BioPharma perspective on remote business developments and the impact?
- As a result, has there been a change in series funding/ IPOs?

Moderated by:
Jeffrey Bockman, PhD
EVP, Oncology Practice Head, Cello Health BioConsulting (Previously Defined Health)

Panelists:
Mark Simon, MBA
Co-founder & Advisor, Torreya Partners
Helen Tayton-Martin, PhD
Chief Business Officer, Adapimmune
Mai-Britt Zocca, PhD
CEO and Founder, IO Biotech

2:35 pm
10 Min Break

2:45 pm
Translational Science and Emerging Biomarkers Plenary Session Part 2

2:45 pm
Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies
- Evaluating single cell omics to understand the heterogeneity in immune and tumor cells
- Multi-omic biomarkers for patient selection in solid tumor IO: is there a path to more personalized therapy?
- In an era of ‘targeted’ therapies against cell-intrinsic mechanisms (e.g., PARP, NTRK, BRAF) and surface molecules (Nectin-4, HER2), is there a path forward for pan-tumor biomarkers, or is multi-tumor more likely to be the dominant development mechanism?

Moderated by:
Theresa LaVallee, PhD
VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy

Jared Lunceford, PhD
Distinguished Scientist, Biostatistics and Research Decision Sciences, Merck Research Laboratories

Angel A Rodriguez, MD
Oncology Medical Director, Natera

Samik Upadhaya, PhD
Research Analyst, Anna-Maria Kellen Clinical Accelerator and Venture Fund, Cancer Research Institute (CRI)

New Speaker

3:25 pm
Five Minute Break
### TRACK A

**3:30 pm**
**Translational Learnings for Cellular Therapies Inform Next-Generation Strategies**

Teresa (Teri) Foy, PhD  
Senior Vice President, Research and Early Development Immuno-Oncology and Cell Therapy, BMS

**3:45 pm**
**AI Coupled with Mass Spectrometry for Immunotherapy Diagnostic Test Development**

Robert Georgantas III, PhD  
SVP, Research and Translational Science, Biodesix

**4:00 pm**
**Accelerating Drug Development in Early Stage Solid Tumors: Novel Digital and Molecular Endpoints for Neoadjuvant/Adjuvant Disease**

David Shames, PhD  
Senior Director, Cancer Immunotherapy Biomarkers & Staff Scientist in Oncology Biomarker Development, Genentech

**4:15 pm**
**Immunai Case Study**

Luis Voloch  
CTO, Immunai  
with  
Noam Solomon, PhD  
Founder & CEO, Immunai

---

### TRACK B

**3:30 pm**
**Industry Perspective on Neoadjuvant and Adjuvant Designs, Challenges and Opportunities**

Nageatte Ibrahim, MD  
Associate Vice President, Global Oncology Clinical Development, Merck

**3:45 pm**
**Ultivue Case Study**

4:00 pm
**ctDNA for Potential Application to Clinical Trial Designs**

Carl Barrett  
VP, Translational Sciences Onc iMed, AstraZeneca

**4:15 pm**
**Single Cell and Spatial Analysis: Mechanisms of Response and Resistance to Immunotherapy**

- Unravel the complex interplay among the immune, tumor and stromal compartments in the tumor microenvironment with single cell and spatial analysis  
- Track the anti-tumor immune response through single cell profiling of T and B cell clonal lineages and phenotypes  
- Uncover the epigenetic regulators of immune cell phenotypes governing response and resistance to immunotherapies  
- Explore published case studies of how multimomic single cell and spatial analysis were applied to advance our understanding of mechanisms driving response and resistance to immunotherapy.

Bruce Adams, PhD  
Staff Scientist, 10X Genomics

---

**4:30 pm**
**10 Min Break**

**Zoom Small Group Interactive Discussions**

**4:40 pm – 5:10 pm EST**

The concluding afternoon of day two will be dedicated to 30 minute small group discussion choices. These interactive discussions are first come first serve and have limited capacity. Registration is required in advance. Registered IO360° attendees may choose one discussion group to attend live over the course of the conference.

To register for the discussion topic of your choice please email service@tcfllc.org with the Subject Line: IO360° Group Discussion Choice.

---

**Single Cell and Spatial Analysis**

Spatial transcription ICD tells you where in the TME each cell of interest (eg Cd8 T cell, MDSC, etc is) and what that cell is expressing at that moment in time. This roundtable will discuss:

- How many and discordant analyses can be combined and what are the limitations there  
- How can we best leverage the information to understand the function and history of each cell  
- How can we connect that information to an understanding of what in the TME is influencing the cell’s function, and what influence that cell has on the TME

Dan Chang, PhD  
Principal Scientist, Single cell sequencing lead, Merck Research Laboratories
Day Four includes the following topics:

- Bispecifics
- Cancer Immunotherapy Debate: TIGIT
- Clinical Developments

8:45 am
IO360° Virtual Platform Opens

This is an opportunity to explore the platform, reach out to fellow attendees and visit the technology and service companies working specifically in immuno-oncology R&D. Partnering Meetings will also be taking place during this time on Meeting Mojo.

9:20 am
Opening Remarks
Kate Woda
Director, IO360°

VIP FIRESIDE CHAT

9:30 am
VIP Fireside Chat: Oriana Sousa’s Immunotherapy Journey

We are honored to welcome Oriana Sousa, the first hypercalcemic small cell ovarian cancer patient in the world to ever receive immunotherapy, who in this fireside chat provides personal insights on her experience with Nivolumab as an experimental therapy.

VIP Patient Guest:
Oriana Sousa
Patient Advocate,

Moderated by:
Theresa LaVallee, PhD
VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy

10:00 am
Diversity and Inclusion and The Impact on IO

This panel will address diversity and inclusion issues that influence the IO space and ways to overcome them.

Moderated by:
Axel Hoos, MD, PhD
SVP, Therapeutic Area Head, Oncology R&D, GSK

Panelists:
Kristen Hege, MD
SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy, BMS
Yvonne Lu
Executive Search and Leadership Consultant, Russell Reynolds Associates
Tracy Vanderslice
Vice President and Head, Global Clinical Sciences & Delivery, GSK

10:50 am
Speaker Meet/Greet Breakouts & Visit the Technology & More Section

This 10 minute session is allotted to meet the speakers from the previous talks in the preclinical session and an opportunity to visit the Technology & More section of the virtual platform.

11:00 am
Ten Minute Break

11:10 am
Modified NK Cells in Combination with anti-CD38 for Multiple Myeloma and Future Therapeutic Areas
Dmitri Wiederschain, PhD
Vice President, Global Head, Immuno-Oncology Research Therapeutic Area, Sanofi

11:30 am
Regeneron’s State of Efforts in Bispecifics and Emerging CoStim Clinical Trial Portfolio
Israel Lowy, MD, PhD
SVP, Clinical Sciences, Head, Translational Science and Oncology, Regeneron Pharmaceuticals

11:45 am
Update on Teclistamab, a B-cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Raluca Verona, PhD
Senior Director, Head of Immune Oncology Translational Research, Janssen R&D

12:00 pm
Stimulation, Function and Next Generation Bispecific T cell Engagement Utilizing an Engineered Multimeric IgM Platform
Daniel Chen, MD, PhD
Chief Medical Officer, IGM Biosciences

---

**ZEITGEIST TALK**

10:30 am
CTLA-4: 10 Years Later

In this talk, GSK’s Dr Axel Hoos, takes a deep dive into the CTLA-4 data over the course of the past 10 years, from its approval, and discusses whether CTLA-4 offers something special beyond melanoma.

Axel Hoos, MD, PhD
SVP, Therapeutic Area Head, Oncology R&D, GSK
12:15 pm  
Tebentafusp: Clinical Validation of a Soluble TCR Bispecific Platform  
David Berman, MD, PhD  
Head, Research and Development, Immunocore

12:30 pm  
Quick Fire Presentations on Solutions that Support Immuno-Oncology R&D

12:40 pm  
Lunch

1:10 pm  
Cancer Immunotherapy Debate  
Cancer Immunotherapy Debate: TIGIT: Is this the Next Big IO Checkpoint Target?  
Roy Baynes, MD  
Global Head, Clinical Development, Merck Research Labs  
Andrew Baum, MD  
Managing Director, Equity Research, Citi  
Moderated by:  
Priti Hegde, MD  
Chief Scientific Officer, Foundation Medicine

Clinical Developments Plenary Session

1:40 pm  
What’s Next: Mercks Expanding IO Pipeline  
Roy Baynes, MD  
Global Head, Clinical Development, Merck Research Labs

1:55 pm  
Keynote 177 MSI High Randomized Data  
Luis Diaz, MD  
Head of the Division of Solid Tumor Oncology; Grayer Family Chair, Memorial Sloan Kettering Cancer Center

2:10 pm  
Bispecific T cell engagers (BiTEs ®) - Clinical Updates in Solid Tumors & Hematological Malignancies  
Dirk Nagorsen, MD, PhD  
Vice President, Early Development TA Head Oncology, Amgen

2:25 pm  
DREAMMing up Advances in MM: Synergistic Potential of Belantamab Mafodotin as Combination Therapy  
Ira Gupta, MD  
Vice President, Medicines Development Leader – Oncology, Genentech

2:40 pm  
CART and Bispecifics: Who’s the Right Candidate?  
In this talk, Dr Deepu Madduri provides a comparison of Bispecifics and CART, addresses what makes a good candidate and how to choose the right patient for each.  
Deepu Madduri, MD  
Assistant Professor of Medicine -Hematology and Medical Oncology; Associate Director, Cellular Therapy Service and Director of Clinical Operations, Center of Excellence for Multiple Myeloma, The Tisch Cancer Institute and Icahn School of Medicine, Mount Sinai

2:55 pm  
Biomarker Findings from anti-PDL1+anti-VEGF Combination Study in Advanced HCC  
Biomarker findings from a 200+ patient phase 1b study on anti-PDL1+anti-VEGF combination in advanced HCC, including tissue multi-omics correlates, digital pathology, ctDNA, and single cell multi-omics analysis will be discussed.  
Yulei Wang, PhD  
Principal Scientist, Oncology Biomarker Development, Genentech

3:10 pm  
Speaker Meet & Greet and Conference Concludes